Chemed (NYSE: CHE) and BioScrip (NASDAQ:BIOS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk.
Insider & Institutional Ownership
95.5% of Chemed shares are owned by institutional investors. Comparatively, 84.5% of BioScrip shares are owned by institutional investors. 4.9% of Chemed shares are owned by insiders. Comparatively, 0.8% of BioScrip shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Chemed has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, BioScrip has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500.
This is a summary of current ratings for Chemed and BioScrip, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Chemed currently has a consensus price target of $266.50, suggesting a potential downside of 19.69%. BioScrip has a consensus price target of $3.56, suggesting a potential upside of 42.50%. Given BioScrip’s stronger consensus rating and higher probable upside, analysts clearly believe BioScrip is more favorable than Chemed.
This table compares Chemed and BioScrip’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Chemed pays an annual dividend of $1.12 per share and has a dividend yield of 0.3%. BioScrip does not pay a dividend. Chemed pays out 20.9% of its earnings in the form of a dividend. Chemed has raised its dividend for 9 consecutive years.
Earnings and Valuation
This table compares Chemed and BioScrip’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Chemed||$1.67 billion||3.17||$98.17 million||$5.36||61.91|
|BioScrip||$817.19 million||0.39||-$64.19 million||($0.44)||-5.68|
Chemed has higher revenue and earnings than BioScrip. BioScrip is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.
Chemed beats BioScrip on 12 of the 16 factors compared between the two stocks.
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and operated territories, independent contractor-operated territories, and franchised locations. This segment also manufactures and sells products and equipment, including drain cleaning machines and drain cleaning solutions. The company was founded in 1970 and is headquartered in Cincinnati, Ohio.
BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.